AC Immune SA
NASDAQ:ACIU
AC Immune SA
NASDAQ:ACIU
Price:
3.45 USD
3.29%
Market Closed
Updated:
May 23, 2024
AC Immune SA
Additional Paid In Capital
|
AC Immune SA
Additional Paid In Capital Peer Comparison
Comparables:
ADCT
CRSP
BSLN
IDIA
KURN
Competitive Additional Paid In Capital Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
AC Immune SA
NASDAQ:ACIU
|
Additional Paid In Capital
CHf474.9m
|
CAGR 3-Years
11%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Additional Paid In Capital
$1.2B
|
CAGR 3-Years
6%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Additional Paid In Capital
$3.2B
|
CAGR 3-Years
9%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Idorsia Ltd
SIX:IDIA
|
Additional Paid In Capital
CHf2.1B
|
CAGR 3-Years
25%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is AC Immune SA's Additional Paid In Capital?
Additional Paid In Capital
474.9m
CHF
474.9m
CHF
Based on the financial report for Dec 31, 2023, AC Immune SA's Additional Paid In Capital amounts to 474.9m CHF.
What is AC Immune SA's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
10%
10%
Over the last year, the Additional Paid In Capital growth was 10%. The average annual Additional Paid In Capital growth rates for AC Immune SA have been 11% over the past three years , 10% over the past five years .
You don't have any saved screeners yet
